Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A

Amy Nowack1*, Erik B. Malarkey1*, Jia Yao1, Adam Bleckert2, Jessica Hill1, Sandra M. Bajjalieh1*

1 Department of Pharmacology, University of Washington, Seattle, Washington, United States of America, 2 Graduate Program in Neurobiology and Behavior, University of Washington, Seattle, Washington, United States of America

Abstract

Levetiracetam is an FDA-approved drug used to treat epilepsy and other disorders of the nervous system. Although it is known that levetiracetam binds the synaptic vesicle protein SV2A, how drug binding affects synaptic functioning remains unknown. Here we report that levetiracetam reverses the effects of excess SV2A in autaptic hippocampal neurons. Expression of an SV2A-EGFP fusion protein produced a 1.5-fold increase in synaptic levels of SV2, and resulted in reduced synaptic release probability. The overexpression phenotype parallels that seen in neurons from SV2 knockout mice, which experience severe seizures. Overexpression of SV2A also increased synaptic levels of the calcium-sensor protein synaptotagmin, an SV2-binding protein whose stability and trafficking are regulated by SV2. Treatment with levetiracetam rescued normal neurotransmission and restored normal levels of SV2 and synaptotagmin at the synapse. These results indicate that changes in SV2 expression in either direction impact neurotransmission, and suggest that levetiracetam may modulate SV2 protein interactions.

Introduction

Levetiracetam ((S)-2-ethyl-2-oxo-pyrrolidine acetamide) represents a new class of drug for the treatment of neurological and psychiatric disorders. Currently marketed as Keppra®, levetiracetam is FDA-approved for the treatment of epilepsy [1], though it also shows promise in the treatment of anxiety disorders [2,3,4], pain [5,6,7], dyskinesias [8,9,10,11,12], and post-traumatic stress disorder [3]. The protein receptor for levetiracetam is Synaptic Vesicle Protein 2A (SV2A) [13], a membrane glycoprotein specific to the secretory vesicles of neurons and endocrine cells in vertebrates [14]. SV2A is both necessary and sufficient for levetiracetam binding [13]. In addition, mice heterozygous for the SV2A gene disruption show reduced response to drug treatment [15], consistent with SV2A being required for levetiracetam action. Thus levetiracetam appears to act by modulating the action of SV2A, though its mechanism of action remains unknown.

Mammals have three SV2 genes that encode the isoforms SV2A, SV2B, and SV2C [16,17,18,19]. Of these, SV2A is the most broadly expressed, and is present in essentially all neurons [20]. Notably, it is the only isoform expressed in many inhibitory, GABAergic neurons [20,21]. SV2A is essential for survival in mice; gene disruption results in severe seizures and premature death [22,23]. At the level of the synapse, SV2 acts as a positive modulator of calcium-dependent exocytosis. Neurons lacking SV2A or SV2A+B display reduced evoked transmitter secretion in excitatory [24,25] and inhibitory [22,26] neurons, as well as in cultured chromaffin cells [27]. In most systems this effect correlates with a reduction in the number of vesicles able to respond to increased presynaptic calcium (the readily releasable pool) [24,25,27]. Thus SV2 appears to act as a positive modulator of secretory vesicle priming in neuroendocrine cells.

Although its structural similarity to the Major Facilitator transporter family suggests that SV2 is a transporter, its demonstrated actions include regulating the expression and trafficking of the calcium binding protein synaptotagmin [28], and affecting presynaptic calcium concentrations [25]. This suggests SV2 may regulate neurotransmission indirectly by controlling the vesicle’s ability to detect changes in presynaptic calcium.

Several studies report a correlation between increased SV2 expression and changes in synaptic functioning. Kindling of seizures in rats results in increased expression of several synaptic vesicle proteins including SV2 [29,30,31], and SV2A is at the hub of seizure-dependent changes in protein co-expression [32]. In addition, mRNA encoding SV2A is a primary target of a microRNA whose expression is sensitive to changes in synaptic activity [33]. Together these findings indicate that altered expression of SV2, and particularly SV2A, is a molecular signature of altered synaptic activity.

In animals subjected to seizure kindling protocols, treatment with levetiracetam blocks both the development of a seizure phenotype and increases in SV2 expression [31,34]. In hippocampal slices from non-epileptic animals, treatment with levetiracetam reduces neurotransmission in response to fast stimuli...
trains [35], consistent with the drug blocking SV2’s effects on vesicle priming. Most interestingly, the latency of drug action is much shorter when neurons are stimulated [36], suggesting that levetiracetam preferentially targets hyperactive synapses.

Here we report the effects of overexpressing SV2A in hippocampal neurons cultured to form autaptic synapses. We found that elevated expression of SV2 resulted in a neurotransmission phenotype that resembled that seen in neurons from SV2 knockout mice, suggesting that too much SV2 is as detrimental to neuronal function as too little. Because the same neurotransmission phenotype is associated with seizures in SV2A knockout mice, this offered the opportunity to assess the effects of levetiracetam under cellular conditions associated with epilepsy.

**Results**

**Expression of SV2A-EGFP in wild-type neurons reduces neurotransmitter release**

We examined the effect of expressing SV2A-EGFP (SV2A with enhanced green fluorescent protein (EGFP) fused to the carboxy terminus) in wild-type autaptic cultures of hippocampal neurons as part of a larger study designed to assess the effects of mutations in SV2 [37]. SV2A-EGFP functions like native SV2, as evidenced by the fact that it restores normal neurotransmission to hippocampal neurons cultured from SV2A/B knockout mice [28,37]. SV2A-EGFP trafficked to presynaptic terminals in wild-type neurons, where it co-localized with the synaptic vesicle protein synaptotagmin and synaptophysin (Figure 1).

To our surprise, expression of SV2A-EGFP in wild-type hippocampal neurons resulted in a neurotransmission phenotype that looked similar to that seen in neurons cultured from SV2A/B knockout mice. As in neurons from SV2A/B knockout mice, action potential-induced excitatory postsynaptic currents (EPSC) were reduced in neurons expressing SV2A-EGFP. EPSC amplitudes were, on average, 65% the amplitude of control neurons expressing just EGFP (Figure 2). More importantly, the hallmark feature of the SV2 knockout phenotype, reduced synaptic depression, was also present in wild-type neurons expressing the SV2A-EGFP construct. Synaptic depression is a form of short-term plasticity that correlates with synaptic release probability [39] and is thus used to measure the ability of synapses to respond to an action potential. In neurons expressing SV2A-EGFP, responses to a 10 Hz stimulus train did not decline to the same extent as in neurons expressing EGFP. This indicates that synaptic release probability is lower when neurons express elevated levels SV2A.

Levetiracetam restores synaptic depression in wild-type neurons expressing SV2A-EGFP

Levetiracetam is reported to have multiple subtle effects on neurons, and the effective concentrations and incubation times for these different effects vary (reviewed in [39]). The ability of levetiracetam to reduce neurotransmission in quiescent neurons requires higher concentrations of drug (100 μM) and relatively long incubation times (≥3 hrs) [35,40]. Thus to determine if levetiracetam altered the neurotransmission effects of SV2A overexpression, we examined synaptic depression, the most robust measure of the overexpression phenotype, in neurons treated with 32 μM or 100 μM levetiracetam for 1 hr or 6–10 hrs. Incubation with 100 μM levetiracetam for 6–10 hr restored normal synaptic depression in neurons expressing SV2A-EGFP (Fig. 3B). Treatment for 6–10 hrs with 32 μM also restored synaptic depression, though the synaptic depression was not of the same magnitude as with the higher dose (Fig. 3A). A 1 hr treatment did not restore normal synaptic depression (not shown). These results show that levetiracetam reverses the synaptic deficit produced by SV2 over-

---

**Figure 1. SV2A-EGFP is trafficked to presynaptic terminals.** Neurons expressing either EGFP or an SV2A-EGFP fusion protein were fixed and processed for immunolabeling. In neurons expressing EGFP green fluorescence was present throughout the length of neurites, whereas in neurons expressing SV2A-EGFP green fluorescence was punctate. Immunolabeling with anti-SV2 and anti-synaptotagmin revealed that the two proteins co-localized. Immunolabeling with anti-synaptotagmin and anti-synaptophysin revealed that synaptotagmin co-localized with synaptophysin. The co-localization of these three presynaptic proteins with SV2A-EGFP indicates that the exogenous fusion protein is trafficked to presynaptic terminals.

doi:10.1371/journal.pone.0029560.g001
Levetiracetam reverses elevated SV2 at synapses expressing SV2A-EGFP

To determine the extent to which exogenous expression of SV2A-EGFP and treatment with levetiracetam affected the amount of SV2 at synapses, we measured synaptic SV2 using immunolabeling. Hippocampal neurons expressing either EGFP or SV2A-EGFP were treated with vehicle (water) or 100 μM levetiracetam for 6 hours, after which they were fixed, permeabilized, and reacted with an anti-SV2 monoclonal antibody [14] that recognizes all three isoforms of SV2. Images were collected on a DeltaVision deconvoluting microscope using identical exposure times and analyzed as described under Methods. Both the total SV2 immunoreactivity per length of neurite and average immunoreactivity intensity at synaptic puncta were quantified. We found that expression of SV2A-EGFP produced a 1.5-fold increase in the average intensity (total puncta intensity/puncta area) of SV2 fluorescent puncta, which indicates that there was more SV2 per synapse in neurons expressing exogenous SV2 than neurons infected with EGFP lentivirus alone. Incubation with levetiracetam reduced this to control levels (Figs. 5A, B). Interestingly, while expression of SV2A-EGFP led to a ~2-fold increase in the total amount of SV2 per unit length of neurite, this increase was not affected by treatment with levetiracetam (Fig. 5C). Together these findings suggest that levetiracetam influences the localization of SV2 at the synapse rather than its overall expression or turnover.

Loss of SV2 results in a significant decrease in the expression levels of synaptotagmin [28,43,44], suggesting that synaptotagmin expression/stability depends on SV2. To determine whether overexpression of SV2 impacts synaptotagmin expression, we assessed the effect of SV2A-EGFP expression on synaptotagmin levels. In cells expressing SV2A-EGFP we observed a ~2-fold increase in the average intensity of anti-synaptotagmin labeled puncta and a ~3-fold increase in the total amount of synaptotagmin (immunoreactivity per unit length of neurite) (Figure 5D–E). Both measures returned to levels seen in control neurons when cultures were incubated with 100 μM levetiracetam for 6 hours. Thus levetiracetam restored both total and synaptic levels of synaptotagmin.

Expression of SV2A-EGFP also increased the density of puncta labeled with anti-synaptotagmin, suggesting that elevated SV2 levels may lead to more synapses. This increase was not affected by treatment with levetiracetam, however (Fig. 5F), so it is not clear that an increase in the number of puncta represents an increase in functional synapses.

We also assessed the overlap of SV2 and synaptotagmin at the synapse to determine if either overexpression and/or treatment with levetiracetam affected protein co-localization at the synapse. Cultures were co-labeled with anti-SV2 and anti-synaptotagmin and the fluorescent intensity of SV2 to synaptotagmin was expressed as a ratio for each punctum. Expression of SV2A-EGFP resulted in a small but significant decrease in the co-localization of the two proteins, and this decrease was not affected by treatment with levetiracetam (Figure 5G).

In summary, we find that levetiracetam treatment of neurons overexpressing SV2A 1) decreased the amount of both SV2 and synaptotagmin at synapses (Figures 4B and 4D), 2) decreased total synaptotagmin/length of neurite but did not restore lower levels of total SV2 (Figures 4C and 4E), and 3) did not alter the ratio of

expression and that the reversal requires concentrations of levetiracetam and incubation times previously shown to be necessary for drug effects on synaptic transmission [35].

As a control, we tested the effects of piracetam, a related compound with poor anti-seizure action [41] and much lower affinity for SV2A [42]. Treatment with 32 μM piracetam for 6–10 hrs did not restore synaptic depression [Fig. 3C]. Treatment with 100 μM piracetam for 6–10 hrs resulted in some synaptic depression [Fig. 3D], though less than half that seen with levetiracetam. This is consistent with the effect occurring via SV2A, which has a higher affinity for levetiracetam than piracetam.

In contrast to the studies performed in hippocampal slice preparations [35], levetiracetam did not affect neurotransmission in uninfected wild type neurons (Fig. 4A) nor did it restore normal EPSC amplitude or synaptic depression to neurons lacking SV2 (Fig. 4B). Thus overexpression of SV2A is required for levetiracetam action in this preparation.

Levetiracetam reverses elevated SV2 at synapses expressing SV2A-EGFP

To determine the extent to which exogenous expression of SV2A-EGFP and treatment with levetiracetam affected the amount of SV2 at synapses, we measured synaptic SV2 using immunolabeling. Hippocampal neurons expressing either EGFP or SV2A-EGFP were treated with vehicle (water) or 100 μM levetiracetam for 6 hours, after which they were fixed, permeabilized, and reacted with an anti-SV2 monoclonal antibody [14] that recognizes all three isoforms of SV2. Images were collected on a DeltaVision deconvoluting microscope using identical exposure times and analyzed as described under Methods. Both the total SV2 immunoreactivity per length of neurite and average immunoreactivity intensity at synaptic puncta were quantified. We found that expression of SV2A-EGFP produced a 1.5-fold increase in the average intensity (total puncta intensity/puncta area) of SV2 fluorescent puncta, which indicates that there was more SV2 per synapse in neurons expressing exogenous SV2 than neurons infected with EGFP lentivirus alone. Incubation with levetiracetam reduced this to control levels (Figs. 5A, B). Interestingly, while expression of SV2A-EGFP led to a ~2-fold increase in the total amount of SV2 per unit length of neurite, this increase was not affected by treatment with levetiracetam (Fig. 5C). Together these findings suggest that levetiracetam influences the localization of SV2 at the synapse rather than its overall expression or turnover.

Loss of SV2 results in a significant decrease in the expression levels of synaptotagmin [28,43,44], suggesting that synaptotagmin expression/stability depends on SV2. To determine whether overexpression of SV2 impacts synaptotagmin expression, we assessed the effect of SV2A-EGFP expression on synaptotagmin levels. In cells expressing SV2A-EGFP we observed a ~2-fold increase in the average intensity of anti-synaptotagmin labeled puncta and a ~3-fold increase in the total amount of synaptotagmin (immunoreactivity per unit length of neurite) (Figure 5D–E). Both measures returned to levels seen in control neurons when cultures were incubated with 100 μM levetiracetam for 6 hours. Thus levetiracetam restored both total and synaptic levels of synaptotagmin.

Expression of SV2A-EGFP also increased the density of puncta labeled with anti-synaptotagmin, suggesting that elevated SV2 levels may lead to more synapses. This increase was not affected by treatment with levetiracetam, however (Fig. 5F), so it is not clear that an increase in the number of puncta represents an increase in functional synapses.

We also assessed the overlap of SV2 and synaptotagmin at the synapse to determine if either overexpression and/or treatment with levetiracetam affected protein co-localization at the synapse. Cultures were co-labeled with anti-SV2 and anti-synaptotagmin and the fluorescent intensity of SV2 to synaptotagmin was expressed as a ratio for each punctum. Expression of SV2A-EGFP resulted in a small but significant decrease in the co-localization of the two proteins, and this decrease was not affected by treatment with levetiracetam (Figure 5G).

In summary, we find that levetiracetam treatment of neurons overexpressing SV2A 1) decreased the amount of both SV2 and synaptotagmin at synapses (Figures 4B and 4D), 2) decreased total synaptotagmin/length of neurite but did not restore lower levels of total SV2 (Figures 4C and 4E), and 3) did not alter the ratio of
SV2/tagmin at synapses. Considered together these findings are consistent with the interpretation that the amount of synaptotagmin at synapses tracks the amount of SV2, and levetiracetam results in a reduction in the amount of both proteins available to support calcium-triggered exocytosis. The fact that both increased and decreased levels of SV2 and synaptotagmin are associated with reduced release probability suggests that optimal levels of these proteins are required for normal neurotransmission, a conclusion consistent with the recent observation that the number of SV2s and synaptotagmins per vesicle is tightly regulated [45].

Discussion

The results presented here demonstrate that overexpression of SV2A produces abnormal neurotransmission that can be rescued by treatment with levetiracetam. Because expression of SV2A-EGFP rescues normal neurotransmission in neurons cultured from SV2A/B knockout mice [28,37], the effects of overexpression are not likely to be a dominant negative effect of expressing a fusion protein. Rather they appear to be due to effects of excess SV2. We note that like SV2, overexpression of the SNARE-binding protein, complexin, also produces a decrease in synaptic release probability that resembles that seen in complexin knockout mice [46,47,48,49,50]. Thus, synaptic functioning can be regulated by both increases and decreases in protein expression, which suggests that proteins at the synapse form complexes that rely on precise stoichiometry in expression levels.

The reduced synaptic release probability we measured in neurons overexpressing SV2 is nearly identical to that seen in neurons from SV2A/B knockout mice, which experience severe seizures [22,23]. Viewed in combination with the results presented here, it appears that changes in SV2 expression in either direction have a similar impact on synaptic functioning. Indeed, both increases and decreases in SV2 expression have been reported to be associated with the presence of seizures. SV2 expression increases with kindling of seizures, and both the appearance of seizures and elevated SV2 expression are reversed by treatment with levetiracetam [29,31]. In contrast, qualitative analyses of expression reveal decreased SV2A expression in temporal lobe epilepsy [51]. Therefore both increased and decreased SV2 may contribute to epilepsy.

A 6–10 hr treatment with levetiracetam reversed the effects of SV2 overexpression. The requirement for longer treatment times was first reported by Yang et al., who showed that levetiracetam-mediated reduction in synaptic transmission required prolonged presence of the drug [35,40]. Together with the observation that
SV2 contributes to the number of assembled SNARE complexes [27], the delayed action of levetiracetam suggests that it (and therefore SV2) influences vesicle priming prior to the penultimate stages of vesicle fusion. Therefore, drug effects will occur after previously primed vesicles are expended. Consistent with this interpretation, synaptic activity decreases the latency of levetiracetam effects in hippocampal slices [36].

Levetiracetam had no effect on neurons that lacked SV2, consistent with the conclusion that the drug acts by binding SV2. Because SV2 expression is limited to presynaptic terminals, this means that levetiracetam affects presynaptic events that regulate synaptic vesicle release.

Given that levetiracetam restored the concentration of SV2 at the synapse (average labeling intensity per synapse area) to control levels without affecting total SV2 per length of neurite, it is most likely that levetiracetam affects the ability of SV2 to concentrate in synapses. This is most consistent with the drug altering SV2's ability to bind to proteins that influence protein trafficking or localization, for example binding to clathrin adaptor proteins or proteins of the cytoskeleton.

The effects of levetiracetam reported here, in combination with the observation that levetiracetam blocks kindling-induced increases in SV2 [34], suggest that levetiracetam may act by reversing the effects of increased SV2 expression. Because SV2 is part of a protein complex [32], one possible mechanism of drug action is that it inhibits SV2 protein interactions. In the case of SV2 overexpression, levetiracetam may inhibit inappropriate interactions that occur when SV2 is over-abundant. What is clear is that levetiracetam’s action on protein levels at synapases represents a novel drug action. Future work into the mechanisms by which levetiracetam produces the effects reported here will provide insight into the etiology of nervous system disorders that are based in aberrant protein expression/function.

Materials and Methods

SV2 knock-out mice

The generation of SV2A and SV2B knockout mice was reported previously [22,44]. These animals were used to obtain two lines of breeders that were SV2A+/−B+/+ or SV2A+/−B−/−. Littermate SV2A+/+B+/+ and SV2A−/−B+/+ mice were obtained by breeding SV2A+/−B+/+ animals. Similarly, SV2A+/+B−/− and SV2A−/−B−/− littermates were obtained by breeding SV2A+/−B−/− animals. All animals were 99.99% C57BL/6. Cultures were generated from mice at postnatal day 0–2. SV2A genotype was determined by PCR before culturing neurons.

The University of Washington IACUC, protocol number 2801-01, approved the use of mice for these studies.
Lentiviral constructs were designed to encode rat SV2A protein with enhanced-GFP (EGFP) on the carboxy terminus. The resulting fusion protein serves as a real-time visual reporter of infection and proper protein trafficking. A control vector was generated encoding EGFP alone. The SV2A-EGFP or EGFP cDNA was then subcloned into the Lentiviral transfer vector pRRL-cPPT-CMV-X-PRE-SIN [53]. Lentiviral helper plasmids (pLP1, pLP2, pLP/VSVG) were from the Virapower packaging mix (Invitrogen).

Cell culture

Primary cultures of hippocampal neurons were prepared as previously described [24]. Hippocampi were isolated and the dentate gyrus was removed. The hippocampi were then incubated in papain, mechanically dissociated, and plated at a density of 2000–3000 cells/cm² on coverslips containing microislands of astrocytes. Astrocyte cultures were derived from wild-type mice. Levetiracetam or piracetam (Sigma Chemical Company) were dissolved in sterile water and added to cultures as a 500 μM stock solution. Cultures were infected with Lentivirions 1–3 days after plating.

Electrophysiology

Whole-cell voltage-clamp recordings were obtained from neurons on single-neuron islands as previously reported [24] except that recordings were performed at 21–23°C. Recordings were performed 10–17 d after plating. For EPSC amplitude measurements, three responses were obtained and averaged for each cell.

Data analysis and statistics

Action potential-evoked EPSPs were analyzed with custom software written in Visual C# (Microsoft, Redmond, WA) as previously described [24]. EPSP amplitudes were determined by subtracting a baseline current (obtained by averaging the period 5 ms before the stimulus) from the peak current of the EPSC.
Responses less than 1 nA were not included. Statistical analyses were performed with Microsoft Excel. Reported data are mean ± SEM. In all cases, t-tests were two-tailed unpaired tests assuming unequal variances. Immunocytochemistry studies were analyzed using one-way ANOVA followed by Fisher's LSD test.

Indirect Immunocytochemistry

For determining the subcellular localization of SV2, cultured neurons were fixed with 4% paraformaldehyde (EM sciences) in phosphate buffered saline (PBS) for 20 min at room temperature. Cells were then washed with PBS containing glycerine (0.1 M). PBS supplemented with 0.2% normal goat serum, 0.1% bovine serum albumin, and 0.4% saponin was used for 10 min to block nonspecific binding and permeabilize cells. The cells were then incubated with primary antibody against SV2 [14] or synaptotagmin [52] overnight at 4°C. Following washout of primary antibodies, cells were incubated with Alexa-Fluor 568 or Alexa-Fluor 657-conjugated secondary antibodies (Invitrogen, 1:2000) for 1 h. Parallel control experiments were performed in which primary antibodies were omitted to test for the nonspecific binding of secondary antibodies. Neurons were imaged at the W. M. Keck Center for Advanced Studies in Neural Signaling using a DeltaVision microscope (Applied Precision, Issaquah, WA) with a 60× oil immersion objective, Sedat quad filter set (Chroma Technologies), Photometrics CH350 CCD camera using Softworx 2.5.0. A z-series of images was collected at a resolution of 0.113 μm/pixel and deconvolved. A representative z-plane was chosen for analysis. Images were processed using MetaMorph (Molecular Devices, Sunnyvale, CA) to measure dendritic length and to detect and count fluorescent puncta larger than four pixels. Colocalization of SV2A and synaptotagmin labeling was measured using MetaMorph. To assess co-localization The percentage of synaptotagmin-positive cell area that was also positive for synaptophysin was assessed. All imaging data were background subtracted using fluorescence emission from a region of the coverslip containing no cells.

Acknowledgments

We thank Lisa Baldwin for managing the animal colony and Drs. Jane Sullivan, Catherine Woolley, and Neil Nathanson for comments on the manuscript.

Author Contributions

Conceived and designed the experiments: AN EM JY SB. Performed the experiments: AN EM JY AB JH SB. Analyzed the data: AN EM JY AB JH SB. Wrote the paper: EM JY SB.

References

1. De Smedt T, Raedt R, Vancx K, Boon P (2007) Levetiracetam: part II, the clinical profile of a novel antiepileptic drug. CNS Drug Rev 13: 57–78.
2. Kimy G, Worthington JJ, Wygant L, Nery F, Reese H, et al. (2007) Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry 68: 1010–1013.
3. Kimy G, Wygant L, Pardo TB, Molo M (2006) Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 67: 211–214.
4. Zhang W, Connor KM, Davidson JR (2005) Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 19: 551–553.
5. Enggaard TP, Kitgaard NA, Sindrup SH (2006) Specific effect of levetiracetam in experimental human pain models. Eur J Pain 10: 185–196.
6. Dunteman ED (2005) Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. J Pain Palliat Care Pharmacother 19: 35–45.
7. Price MJ (2004) Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain 20: 53–56.
8. Bubara KO, Malik T, Exconde RE (2005) The effect of levetiracetam on essential tremor. Neurology 64: 1078–1080.
9. McGavin CL, John Y, Musser WS (2005) Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology 61: 419.
10. Woods SW, Saka JR, Baker CB, Cohen SJ, Tolk C (2008) Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 69: 546–554.
11. Zivkovic SA, Costa G, Bond G, Abou-Elmaagd KM (2008) Treatment of tardive dyskinesia with levetiracetam in a transplant patient. Acta Neurol Scand 117: 351–353.
12. Striano P, Elefante A, Coppola A, Tortora F, Zara F, et al. (2005) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101: 4986–4991.
13. Buckney B, Kelly RB (1985) Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. Journal of Cell Biology 100: 1284–1294.
14. Lynch BA, Lamberg N, Nocka K, Kense-Hammes P, Bajjalieh SM, et al. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101: 9806–9816.
15. Buckney B, Kelly RB (1985) Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. Journal of Cell Biology 100: 1284–1294.
16. Kaminski RM, Gillard M, Leveque K, Hanon E, Loerant G, et al. (2009) Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 50: 1729–1740.
17. Bajjalieh SM, Peterson K, Linial M, Scheller RH (1993) Brain contains two forms of synaptic vesicle protein 2. Proceedings of the National Academy of Sciences USA 90: 2150–2154.
18. Bajjalieh SM, Peterson K, Shinghal R, Scheller RH (1992) SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 257: 1271–1273.
19. Farny MB, Lee S, Edwards RH, Buckney KM (1992) The synaptic vesicle protein SV2 is a novel type of neurotransmitter transporter. Cell 70: 861–867.
20. Bajjalieh SM, Franz G, Weimann JM, McConnell SK, Scheller RH (1994) Differential expression of Synaptic Vesicle Protein 2 (SV2) isoforms. The Journal of Neuroscience 14: 5223–5235.
21. Gronborg M, Pavlos NJ, Brunk I, Chua JJ, Munster-Wandowski A, et al. (2010) Quantitative comparison of glutamatergic and GABAergic synaptic vesicles reveals selectivity for few proteins including MAL2, a novel synaptic vesicle protein. J Neurosci 30: 2–12.
22. Crowder KM, Gunther JM, Jones TA, Hale RD, Zhang H-Z, et al. (1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proceedings of the National Academy of Science, USA 96: 115268–115273.
23. Janz R, Goda Y, Geppert M, Misler M, Sudhof TC (1999) SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24: 1003–1016.
24. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM (2006) Synaptic vesicle protein 2 enhances release probability at quisqualate synapses. J Neurosci 26: 1303–1313.
25. Wai QF, Zhou Z-Y, Thakur P, Vila A, Sherry DM, et al. (2010) SV2 acts via presynaptic calcium to regulate neurotransmitter release. Neuron 66: 684–695.
26. Chang WP, Sudhof TC (2003) SV2 renders primed synaptic vesicles competent for Ca2+ induced exocytosis. J Neuroscience 29: 883–897.
27. Xu T, Bajjalieh SM (2001) SV2 modulates the size of the readily releasable pool of secretory vesicles. Nature Cell Biology 3: 691–698.
28. Yao J, Nowack A, Kense-Hammes P, Gardner RG, Bajjalieh SM (2010) Corelfactoring of SV2 and synaptotagmin at the synapse. J Neurosci 30: 5369–5378.
29. Matveeva EA, Vanaman TG, Whiteheart SW, Slavin JT (2007) Asymmetric accumulation of hippocampal 7S SNARE complexes occurs regardless of kindling paradigm. Epilepsy Res 73: 266–274.
30. Matveeva EA, Whiteheart SW, Slavin JT (2003) Accumulation of 7S SNARE complexes in hippocampal synaptosomes from chronically kindled rats. J Neurochem 84: 962–964.
31. Olivo Y, Iihara S, Terada R, Kikuta M, Sofie N, et al. (2009) Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentyleneetrazole kindling. Biochem Biophys Res Commun 390: 415–420.
32. Winden KD, Karsten SL, Brajin A, Kado LG, Gehman L, et al. (2011) A systems level, functional genomics analysis of chronic epilepsy. PLoS One 6: e007653.
33. Cohen JE, Lee PR, Chen S, Li W, Fields RD (2011) MicroRNA regulation of homostatic synaptic plasticity. Proc Natl Acad Sci USA 108: 11630–11635.
34. Matveeva EA, Vanaman TG, Whiteheart SW, Slavin JT (2008) Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes. Epilepsy 48: 1749–1758.
35. Yang XF, Wiesendfeld A, Rothman SM (2007) Prolonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission. Epilepsia 48: 1861–1869.
36. Meehan AL, Yang X, McAdams BD, Yuan L, Rothman SM (2011) A New Mechanism for Antiepileptic Drug Action: Vesicular Entry May Mediate the Effects of Levetiracetam. J Neurophysiol 106: 1227–1239.
37. Nowack A, Yao J, Custer KL, Bajjalieh SM (2010) SV2 regulates neurotransmitter release via multiple mechanisms. Am J Physiol Cell Physiol 299: C960–967.
38. Dobrunz LE, Stevens CF (1997) Heterogeneity of release probability, facilitation, and depletion at central synapses. Neuron 18: 995–1008.
39. De Smedt T, Raedt R, Vonck K, Boon P (2007) Levetiracetam: the profile of a novel anticonvulsant drug part I: preclinical data. CNS Drug Rev 13: 43–56.
40. Yang XF, Rothman SM (2009) Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission. Seizure 18: 615–619.
41. Gower AJ, Hirsch E, Boehrer A, Noyer M, Marescaux C (1995) Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 22: 207–213.
42. Noyer M, Gillard M, Matague A, Henrichart JP, Wullert E (1995) The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 296: 137–146.
43. Lazzell DR, Belzuz J, Thakur P, Sherry DM, Janz R (2004) SV2B regulates synaptotagmin 1 by direct interaction. J Biol Chem 279: 52124–52131.
44. Morgans CW, Kenseel-Hammes P, Hurley JB, Burton K, Idzerda R, et al. (2009) Loss of the Synaptic Vesicle Protein SV2B results in reduced neurotransmission and altered synaptic vesicle protein expression in the retina. PLoS ONE 4: e5230.
45. Mutch SA, Kenseel-Hammes P, Gaddel JC, Fujimoto BS, Allen RW, et al. (2011) Protein quantification at the single vesicle level reveals that a subset of synaptic vesicle proteins are trafficked with high precision. J Neurosci 31: 1461–1470.
46. Abderrahmani A, Niederhauser G, Plaisance V, Roehrlich ME, Lenain V, et al. (2004) Complexin I regulates glucose-induced secretion in pancreatic beta-cells. J Cell Sci 117: 2239–2247.
47. Huttner WB, Schiebler P, Greengard P, De Camilli P (1983) Synapsin I (protein I), a nerve terminal-specific phosphoprotein, III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. Journal of Cell Biology 96: 1373–1380.
48. Itakura M, Misawa H, Sekiguchi M, Takahashi S, Takahashi M (1999) Transfection analysis of functional roles of complexin I and II in the exocytosis of two different types of secretory vesicles. Biochem Biophys Res Commun 265: 691–696.
49. Liu J, Guo T, Wu J, Bai X, Zhou Q, et al. (2007) Overexpression of complexin in PC12 cells inhibits exocytosis by preventing SNARE complex recycling. Biochemistry (Mosc) 72: 439–444.
50. Xue M, Reim K, Chen X, Chao HT, Deng H, et al. (2007) Distinct domains of complexin I differentially regulate neurotransmitter release. Nat Struct Mol Biol 14: 949–958.
51. van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA (2008) Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia 50: 422–433.
52. Schiell AE, Batchelor RH, Bajjalieh SM (1996) Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. Journal of Biological Chemistry 271: 27770–27775.
53. Barry SC, Harder B, Brzezinski M, Flint LY, Seppen J, et al. (2001) Lentivirus vectors encoding both central polyuridine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Hum Gene Ther 12: 1103–1108.